Advertisement


Lucy Gilbert, MD, on Overall Survival by Prior Taxane Use in the Phase III ROSELLA Trial

ASCO 2026

Advertisement

Lucy Gilbert, MD, of McGill University Health Centre, discusses subgroup analyses from the ROSELLA study. Relacorilant plus nab-paclitaxel demonstrated a statistically and clinically significant overall survival benefit in patients with platinum-resistant ovarian cancer compared to a weekly taxane; subgroup analyses for overall survival showed a consistent benefit favoring the addition of relacorilant to nab-paclitaxel irrespective of prior taxane use (Abstract 5503). 



Related Videos

Prostate Cancer

Adam Kibel, MD, on PROTEUS Trial in High-Risk Prostate Cancer: A Surgical Oncologist’s Perspective

Adam Kibel, MD, of Brigham and Women's Hospital, discusses findings from the phase III PROTEUS trial, which evaluated perioperative (neoadjuvant and adjuvant) apalutamide and androgen deprivation therapy vs placebo and ADT with radical prostatectomy in patients with high-risk localized or locally advanced prostate cancer. Dr. Kibel talks about how the regimen of apalutamide and ADT affects both the surgical procedure itself as well as patient outcomes postprocedure (Abstract LBA1).

Breast Cancer

Sara A. Hurvitz, MD, FACP, on Metastatic Triple-Negative Breast Cancer: More Results From ASCENT-03

Sara A. Hurvitz, MD, FACP, of Fred Hutchinson Cancer Center, provides an update focusing on progression-free survival after next line of treatment and subsequent therapies among patients enrolled in the ASCENT-03 trial. The study compared sacituzumab govitecan vs chemotherapy in patients with previously untreated metastatic triple-negative breast cancer (Abstract 1001).

Lung Cancer
Pancreatic Cancer

Julie R. Gralow, MD, FACP, FASCO, on Highlights of the 2026 ASCO Annual Meeting

Julie R. Gralow, MD, FACP, FASCO, Chief Medical Officer and Executive Vice President of ASCO, provides an overview of the highlights of this year’s meeting, including practice-changing data included in the Plenary Session.

Lymphoma

John M. Burke, MD, on Newly Diagnosed DLBCL: frontMIND Trial

John M. Burke, MD, of SCRI at Rocky Mountain Cancer Centers I The US Oncology Network, presents findings from the phase III frontMIND trial, which evaluated tafasitamab plus lenalidomide and R-CHOP in patients newly diagnosed with diffuse large B-cell lymphoma (Abstract LBA7000).

Bladder Cancer

Gopa Iyer, MD, on LY4052031 for Advanced or Metastatic Urothelial Carcinoma

Gopa Iyer, MD, of Memorial Sloan Kettering Cancer Center, presents initial results from the phase I NEXUS-01 study, which evaluated LY4052031, an antibody-drug conjugate targeting Nectin-4, in patients with advanced or metastatic urothelial carcinoma (Abstract 4508). 

Advertisement

Advertisement




Advertisement